FDA Brief

Warning letters Food

FDA warning letter to

Bee Healthy Farms LLC

LowIssued May 3, 2023Posted Jul 11, 2023Division of Human and Animal Food Operations West II

FDA warned Bee Healthy Farms that website claims made its propolis, royal jelly, honey, and gum products unapproved and misbranded drugs.

What happened

FDA reviewed Bee Healthy Farms’ website www.beehealthyfarms.com in September and October 2022 and again in March and April 2023, and also reviewed its blog. The website takes orders for six bee-derived products and includes claims that they treat or prevent diseases, such as antibacterial, antiviral, antitumor, sore throat, flu, hypertension, and inflammation claims. FDA says those claims make the products drugs that are not approved and lack adequate directions for use.

What FDA found

  1. The website claims show the products are intended to treat, prevent, or mitigate diseases, so FDA treats them as drugs.

    Section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are new drugs because they are not generally recognized as safe and effective for those uses and FDA has not approved them.

    Sections 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The products lack adequate directions for a layperson to use them safely for the claimed disease uses, so they are misbranded.

    Section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. Selling these misbranded drugs in interstate commerce violates the Act.

    Section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt with the specific steps taken to address the violations, an explanation of steps to prevent recurrence, and related documentation. If corrective actions cannot be completed in that time, the company must state the reason for delay and when it will finish.

Who should pay attention

  • dietary supplement brands selling propolis, honey, or royal jelly
  • e-commerce sellers that make disease-treatment claims on websites or blogs
  • retailers and distributors of bee-derived supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk